[CAS NO. 57818-44-7] ABTL-0812
PRODUCTS SPECIFICATIONS [57818-44-7]
DESCRIPTION [57818-44-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 296.44 |
| Molecular Formula | C18H32O3 |
| SMILES | CCCCC/C=C\C/C=C\CCCCCCC(O)C(O)=O |
Summary
In Vitro
ABTL-0812 (ABTL0812; 10-100 μM; 48 hours) inhibits cell viability of squamous NSCLC H157 cells
[1]
.
Compared with squamous NSCLC H157 cells, human lung fibroblast cell line MRC-5 are resistant to ABTL0812 treatment
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | Human lung fibroblast MRC5 and squamous non-small cell lung (NSCLC) H157 cells |
| Concentration: | 10, 30, 100 μM |
| Incubation Time: | 48 hours |
| Result: | Inhibited cell viability of squamous NSCLC H157 cells, not lung fibroblast cell line MRC-5. |
In Vivo
ABTL-0812 (ABTL0812; 120 mg/kg; oral gavage; 5 times per week; for 33 d) induces ER stress in human lung and pancreatic xenografts
[1]
.
ABTL-0812 induces hallmarks of ER stress in vivo. ABTL-0812 increases ATF4 and HSPA5 expression in mice bearing MiaPaca2 and A549 xenograft, respectively
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Athymic female nude mice bearing MiaPaca2 and A549 xenograft models [1] |
| Dosage: | 120 mg/kg |
| Administration: | Administered by oral gavage; 5 times per week for 33 days |
| Result: | Induced ER stress in human lung and pancreatic xenografts. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03366480 | Ability Pharmaceuticals SL|Hospital Vall d´Hebron|Institut Català d´Oncologia|Hospital Clínico Universitario de Valencia|Hospitales Universitarios Virgen del Rocío|Centre Leon Berard|Institut Paoli-Calmettes|Gustave Roussy, Cancer Campus, Grand Paris |
Endometrial Cancer|Squamous Non-Small Cell Lung Cancer
|
December 1, 2016 | Phase 1|Phase 2 |
| NCT04431258 | Ability Pharmaceuticals SL |
Pancreatic Cancer
|
May 6, 2021 | Phase 1|Phase 2 |
| NCT02201823 | Ability Pharmaceuticals SL|Hospital Clinic of Barcelona|Institut Català d´Oncologia |
Cancer
|
February 2014 | Phase 1 |
| NCT03417921 | Ability Pharmaceuticals SL|The Cleveland Clinic |
Pancreatic Cancer
|
December 1, 2020 | Phase 1|Phase 2 |
Appearance
Liquid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Pure form | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 250 mg/mL ( 843.34 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.3734 mL | 16.8668 mL | 33.7336 mL |
| 5 mM | 0.6747 mL | 3.3734 mL | 6.7467 mL |
| 10 mM | 0.3373 mL | 1.6867 mL | 3.3734 mL |
Synonyms
